High out-of-pocket costs are a growing problem in healthcare, often creating stress and confusion for patients. A new analysis in Circulation: Cardiovascular Quality and Outcomes examined one way that physicians can help. 

Amgen’s newly created subsidiary, Pillartree Limited, will acquire Horizon Therapeutics for $116.50 per share in cash. That’s a premium of 19.7% above the closing price of $97.29 on Dec. 9, 2022.

According to data submitted to the FDA, the platform has been linked to an accuracy of 90%, sensitivity of 87.8% and specificity of 83%.

Diagnostic catheters, ablation catheters and stents are just some of the solutions cardiologists are now struggling to obtain.

A new scientific statement from the American Heart Association examined the potential impact of many therapies, including fish oil supplements, lily of the valley and yoga.

It is an announcement many interventional cardiologists have been waiting to hear for a long time. 

Oversized devices are becoming more common as time goes on, which suggests operators are growing increasingly comfortable with this treatment choice.

The Impella RP System is still associated with significant benefits, the FDA said, but there are certain high-risk patients who should no longer be eligible for treatment.